Clinical pharmacist, Al-Salam Teaching Hospital, Mosul, Iraq.
Department of Pharmacology, College of Medicine, Baghdad University, Iraq.
Int J Infect Dis. 2022 Jan;114:79-84. doi: 10.1016/j.ijid.2021.10.012. Epub 2021 Oct 12.
This study aimed to determine the effect of melatonin on thrombosis, sepsis, and mortality rate in adult patients with severe coronavirus infection (COVID-19).
This single-center, prospective, randomized clinical trial was conducted from 1 December 2020 to 1 June 2021 at Al-Shifaa hospital in Mosul, Iraq. There were 158 patients with severe COVID-19 included in the study: 82 in the melatonin group (who received 10 mg melatonin in addition to standard therapeutic care) and 76 in the control group (given standard therapeutic care only). Patients were chosen by a blocked randomization design. The physician then evaluated and recorded the incidence of thrombosis, sepsis, and mortality rate on days 5, 11, and 17 of symptoms.
The intervention group consisted of 82 patients, while the control group consisted of 76 patients. In comparison to the control group, thrombosis and sepsis developed significantly less frequently (P < 0.05) in the melatonin group during the second week of infection, while mortality was significantly higher in the control group (P < 0.05).
Adjuvant use of melatonin may help to reduce thrombosis, sepsis, and mortality in COVID-19 patients.
本研究旨在确定褪黑素对重症冠状病毒感染（COVID-19）成年患者血栓形成、脓毒症和死亡率的影响。
这是一项于 2020 年 12 月 1 日至 2021 年 6 月 1 日在伊拉克摩苏尔 Al-Shifaa 医院进行的单中心、前瞻性、随机临床试验。共有 158 例重症 COVID-19 患者纳入研究：褪黑素组 82 例（在标准治疗护理的基础上加用 10mg 褪黑素），对照组 76 例（仅给予标准治疗护理）。患者采用区组随机设计选择。然后，医生在症状出现后的第 5、11 和 17 天评估并记录血栓形成、脓毒症和死亡率的发生率。
干预组有 82 例患者，对照组有 76 例患者。与对照组相比，褪黑素组在感染的第二周内血栓形成和脓毒症的发生率明显较低（P<0.05），而对照组的死亡率明显较高（P<0.05）。
褪黑素的辅助使用可能有助于降低 COVID-19 患者的血栓形成、脓毒症和死亡率。
Zotero 插件